William V. Skillman. See information in "Management Team". Bill serves as the Chairman of the Board as well as President and CEO of Velico Medical
Roger Y. Dodd, Ph.D. is an internationally acclaimed leader in the field of transfusion medicine and has significant experience and expertise in the area of biomedical research and development. Dr. Dodd recently retired as Vice President, Biomedical Research and Development at the Jerome H. Holland Laboratories of the American Red Cross. His tenure with the American Red Cross extended for more than 40 years. Dr. Dodd was responsible for American Red Cross research programs supporting its blood program. He has more than 175 publications and has edited three books on transfusion transmitted infections. He has been an Advisor to the World Health Organization and he serves on the editorial boards of Transfusion and Transfusion Medicine. Dr. Dodd is a past-president of the American Association of Blood Banks and currently serves on the Board of International Society of Blood Transfusion as Secretary General. He has received the Morten Grove-Rasmussen and Emily Cooley Memorial Awards from the AABB; a Tiffany Award from the American Red Cross; and the John Snow award from the American Public Health Association. Dr. Dodd holds a Bachelor of Science degree with Honors in Biochemistry from the University of Sheffield (England). He earned a Ph.D. in Immunology from George Washington University.
Rolf Kaelin has served as a director since June 2001. He has more than 20 years of international experience in investment banking and asset management. Until April 2013, Mr. Kaelin was a director of ProgressNow! invest AG, a Swiss venture capital firm and our largest stockholder. He is also a founder and Managing Director of Kaelin Management AG, a Swiss management firm. From 1995 to 1998, Mr. Kaelin served as Head of Corporate Development for Liechtenstein Global Trust. Mr. Kaelin is a graduate of executive studies at the Hendon College, England and completed the Advanced Management Program at The Wharton School of the University of Pennsylvania.
Robert W. Middleton is a co‑founder of the Company and has served as a director since May 1991. Most recently, he was Managing Director, The Middleton Group Division, Source Capital Group, Inc. His immediately prior position was Chairman of The Middleton Group, LLC, an affiliate of Gemini Financial Corporation. Mr. Middleton’s other prior positions, all involving investment banking for medical and high technology companies, include those with Trautman Kramer & Company, Inc., C. L. King & Associates, Inc. and Barclay Investments, Inc. Prior to these activities, he was a General Partner with Fahnestock & Company and held various positions with Burgess & Leith, Inc., including Senior Vice President and director. He attended Princeton University.
Thomas P. Stossel, M.D. has served as a director since April 2000. He is the American Cancer Society Clinical Research Professor of Medicine at the Harvard Medical School as well as Senior Physician in the Hematology Division at Brigham & Women’s Hospital in Boston. For his contributions to blood research, Dr. Stossel has been elected to the National Academy of Sciences, The Institute of Medicine, and the American Academy of Arts and Sciences. He has been awarded honorary M.D. degrees from the University of Linköping, Sweden, and the University of Geneva, Switzerland, and was awarded the American Society of Hematology’s Damashek and Thomas Prizes. Dr. Stossel is the author of numerous scientific publications and of two hematology textbooks. He was Editor-in-Chief of the Journal of Clinical Investigation and is currently Editor-in-Chief of Current Opinion in Hematology. He served on the Scientific Advisory Boards of Biogen, Inc. and Dyax Corp and is founding scientist and a director of Critical Biologics Corporation. Dr. Stossel earned an A.B., summa cum laude, from Princeton University where he received the Kennedy and Class of 1868 Prizes for English Literature, and received his M.D., cum laude, and the Resnick Prize for student research from Harvard Medical School.